Cuvitoglu Ali, Zhou Joseph X, Huang Sui, Isik Zerrin
1 Computer Engineering Department, Dokuz Eylul University, Tinaztepe Kampusu, Izmir 35160, Turkey.
2 Institute for Systems Biology, 401 Terry Ave. N. Seattle, WA 98109, USA.
J Bioinform Comput Biol. 2019 Apr;17(2):1950012. doi: 10.1142/S0219720019500124.
Identification of effective drug combinations for patients is an expensive and time-consuming procedure, especially for experiments. To accelerate the synergistic drug discovery process, we present a new classification model to identify more effective anti-cancer drug pairs using network biology approach. Based on the hypotheses that the drug synergy comes from the collective effects on the biological network, therefore, we developed six network biology features, including overlap and distance of drug perturbation network, that were derived by using individual drug-perturbed transcriptome profiles and the relevant biological network analysis. Using publicly available drug synergy databases and three machine-learning (ML) methods, the model was trained to discriminate the positive (synergistic) and negative (nonsynergistic) drug combinations. The proposed models were evaluated on the test cases to predict the most promising network biology feature, which is the network degree activity, i.e. the synergistic effect between drug pairs is mainly accounted by the complementary signaling pathways or molecular networks from two drugs.
为患者确定有效的药物组合是一个昂贵且耗时的过程,尤其是对于实验而言。为了加速协同药物发现过程,我们提出了一种新的分类模型,以使用网络生物学方法识别更有效的抗癌药物对。基于药物协同作用源于对生物网络的集体效应这一假设,因此,我们开发了六个网络生物学特征,包括药物扰动网络的重叠和距离,这些特征是通过使用个体药物扰动的转录组谱和相关生物网络分析得出的。利用公开可用的药物协同作用数据库和三种机器学习(ML)方法,对该模型进行训练,以区分阳性(协同)和阴性(非协同)药物组合。在测试案例上对所提出的模型进行评估,以预测最有前景的网络生物学特征,即网络度活性,即药物对之间的协同效应主要由两种药物的互补信号通路或分子网络所决定。